0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global PEGylated Granulocyte-Colony Stimulating Factor Market Research Report 2024
Published Date: November 2024
|
Report Code: QYRE-Auto-30H18268
Home | Market Reports | Health| Pharmacy
Global PEGylated Granulocyte Colony Stimulating Factor Market Research Report 2024
BUY CHAPTERS

Global PEGylated Granulocyte-Colony Stimulating Factor Market Research Report 2024

Code: QYRE-Auto-30H18268
Report
November 2024
Pages:90
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

PEGylated Granulocyte-Colony Stimulating Factor Market

The global PEGylated Granulocyte-Colony Stimulating Factor market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
PEGylated Granulocyte-Colony Stimulating Factor (G-CSF) is a long-acting form of G-CSF in which the protein is chemically linked to polyethylene glycol (PEG), a biocompatible molecule that increases its size and stability, reducing renal clearance and extending its half-life in the bloodstream. This PEGylation allows for sustained stimulation of neutrophil production, reducing the frequency of administration needed to manage neutropenia (low neutrophil count) in patients undergoing chemotherapy or with conditions that weaken immune function.
North American market for PEGylated Granulocyte-Colony Stimulating Factor is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for PEGylated Granulocyte-Colony Stimulating Factor is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of PEGylated Granulocyte-Colony Stimulating Factor include Amgen, Mylan, Kashiv BioSciences, Pfizer, Fresenius Kabi, Coherus BioSciences, Sandoz, Jiangsu Hengrui Pharmaceuticals, Amoytop Biotech, Qilu Pharmaceutical, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for PEGylated Granulocyte-Colony Stimulating Factor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding PEGylated Granulocyte-Colony Stimulating Factor.
The PEGylated Granulocyte-Colony Stimulating Factor market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global PEGylated Granulocyte-Colony Stimulating Factor market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the PEGylated Granulocyte-Colony Stimulating Factor manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of PEGylated Granulocyte-Colony Stimulating Factor Market Report

Report Metric Details
Report Name PEGylated Granulocyte-Colony Stimulating Factor Market
Segment by Type
Segment by Application
  • Hospital and Clinic
  • Pharmacy
  • Other
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Amgen, Mylan, Kashiv BioSciences, Pfizer, Fresenius Kabi, Coherus BioSciences, Sandoz, Jiangsu Hengrui Pharmaceuticals, Amoytop Biotech, Qilu Pharmaceutical, CSPC Baike Biopharma, SL Pharm, Lunan Pharmaceutical
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of PEGylated Granulocyte-Colony Stimulating Factor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of PEGylated Granulocyte-Colony Stimulating Factor in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the PEGylated Granulocyte-Colony Stimulating Factor Market report?

Ans: The main players in the PEGylated Granulocyte-Colony Stimulating Factor Market are Amgen, Mylan, Kashiv BioSciences, Pfizer, Fresenius Kabi, Coherus BioSciences, Sandoz, Jiangsu Hengrui Pharmaceuticals, Amoytop Biotech, Qilu Pharmaceutical, CSPC Baike Biopharma, SL Pharm, Lunan Pharmaceutical

What are the Application segmentation covered in the PEGylated Granulocyte-Colony Stimulating Factor Market report?

Ans: The Applications covered in the PEGylated Granulocyte-Colony Stimulating Factor Market report are Hospital and Clinic, Pharmacy, Other

What are the Type segmentation covered in the PEGylated Granulocyte-Colony Stimulating Factor Market report?

Ans: The Types covered in the PEGylated Granulocyte-Colony Stimulating Factor Market report are Pegfilgrastim, Mecapegfilgrastim, Telpegfilgrastim, Other

Recommended Reports

G-CSF and Neutropenia

Stem Cell & Hematopoiesis

PEGylation & Protein Therapeutics

1 PEGylated Granulocyte-Colony Stimulating Factor Market Overview
1.1 Product Definition
1.2 PEGylated Granulocyte-Colony Stimulating Factor by Type
1.2.1 Global PEGylated Granulocyte-Colony Stimulating Factor Market Value Comparison by Type (2024-2030)
1.2.2 Pegfilgrastim
1.2.3 Mecapegfilgrastim
1.2.4 Telpegfilgrastim
1.2.5 Other
1.3 PEGylated Granulocyte-Colony Stimulating Factor by Application
1.3.1 Global PEGylated Granulocyte-Colony Stimulating Factor Market Value by Application (2024-2030)
1.3.2 Hospital and Clinic
1.3.3 Pharmacy
1.3.4 Other
1.4 Global PEGylated Granulocyte-Colony Stimulating Factor Market Size Estimates and Forecasts
1.4.1 Global PEGylated Granulocyte-Colony Stimulating Factor Revenue 2019-2030
1.4.2 Global PEGylated Granulocyte-Colony Stimulating Factor Sales 2019-2030
1.4.3 Global PEGylated Granulocyte-Colony Stimulating Factor Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 PEGylated Granulocyte-Colony Stimulating Factor Market Competition by Manufacturers
2.1 Global PEGylated Granulocyte-Colony Stimulating Factor Sales Market Share by Manufacturers (2019-2024)
2.2 Global PEGylated Granulocyte-Colony Stimulating Factor Revenue Market Share by Manufacturers (2019-2024)
2.3 Global PEGylated Granulocyte-Colony Stimulating Factor Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of PEGylated Granulocyte-Colony Stimulating Factor, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of PEGylated Granulocyte-Colony Stimulating Factor, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of PEGylated Granulocyte-Colony Stimulating Factor, Product Type & Application
2.7 Global Key Manufacturers of PEGylated Granulocyte-Colony Stimulating Factor, Date of Enter into This Industry
2.8 Global PEGylated Granulocyte-Colony Stimulating Factor Market Competitive Situation and Trends
2.8.1 Global PEGylated Granulocyte-Colony Stimulating Factor Market Concentration Rate
2.8.2 The Global 5 and 10 Largest PEGylated Granulocyte-Colony Stimulating Factor Players Market Share by Revenue
2.8.3 Global PEGylated Granulocyte-Colony Stimulating Factor Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global PEGylated Granulocyte-Colony Stimulating Factor Market Scenario by Region
3.1 Global PEGylated Granulocyte-Colony Stimulating Factor Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global PEGylated Granulocyte-Colony Stimulating Factor Sales by Region: 2019-2030
3.2.1 Global PEGylated Granulocyte-Colony Stimulating Factor Sales by Region: 2019-2024
3.2.2 Global PEGylated Granulocyte-Colony Stimulating Factor Sales by Region: 2025-2030
3.3 Global PEGylated Granulocyte-Colony Stimulating Factor Revenue by Region: 2019-2030
3.3.1 Global PEGylated Granulocyte-Colony Stimulating Factor Revenue by Region: 2019-2024
3.3.2 Global PEGylated Granulocyte-Colony Stimulating Factor Revenue by Region: 2025-2030
3.4 North America PEGylated Granulocyte-Colony Stimulating Factor Market Facts & Figures by Country
3.4.1 North America PEGylated Granulocyte-Colony Stimulating Factor Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America PEGylated Granulocyte-Colony Stimulating Factor Sales by Country (2019-2030)
3.4.3 North America PEGylated Granulocyte-Colony Stimulating Factor Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe PEGylated Granulocyte-Colony Stimulating Factor Market Facts & Figures by Country
3.5.1 Europe PEGylated Granulocyte-Colony Stimulating Factor Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe PEGylated Granulocyte-Colony Stimulating Factor Sales by Country (2019-2030)
3.5.3 Europe PEGylated Granulocyte-Colony Stimulating Factor Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific PEGylated Granulocyte-Colony Stimulating Factor Market Facts & Figures by Region
3.6.1 Asia Pacific PEGylated Granulocyte-Colony Stimulating Factor Market Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific PEGylated Granulocyte-Colony Stimulating Factor Sales by Region (2019-2030)
3.6.3 Asia Pacific PEGylated Granulocyte-Colony Stimulating Factor Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America PEGylated Granulocyte-Colony Stimulating Factor Market Facts & Figures by Country
3.7.1 Latin America PEGylated Granulocyte-Colony Stimulating Factor Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America PEGylated Granulocyte-Colony Stimulating Factor Sales by Country (2019-2030)
3.7.3 Latin America PEGylated Granulocyte-Colony Stimulating Factor Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa PEGylated Granulocyte-Colony Stimulating Factor Market Facts & Figures by Country
3.8.1 Middle East and Africa PEGylated Granulocyte-Colony Stimulating Factor Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa PEGylated Granulocyte-Colony Stimulating Factor Sales by Country (2019-2030)
3.8.3 Middle East and Africa PEGylated Granulocyte-Colony Stimulating Factor Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global PEGylated Granulocyte-Colony Stimulating Factor Sales by Type (2019-2030)
4.1.1 Global PEGylated Granulocyte-Colony Stimulating Factor Sales by Type (2019-2024)
4.1.2 Global PEGylated Granulocyte-Colony Stimulating Factor Sales by Type (2025-2030)
4.1.3 Global PEGylated Granulocyte-Colony Stimulating Factor Sales Market Share by Type (2019-2030)
4.2 Global PEGylated Granulocyte-Colony Stimulating Factor Revenue by Type (2019-2030)
4.2.1 Global PEGylated Granulocyte-Colony Stimulating Factor Revenue by Type (2019-2024)
4.2.2 Global PEGylated Granulocyte-Colony Stimulating Factor Revenue by Type (2025-2030)
4.2.3 Global PEGylated Granulocyte-Colony Stimulating Factor Revenue Market Share by Type (2019-2030)
4.3 Global PEGylated Granulocyte-Colony Stimulating Factor Price by Type (2019-2030)
5 Segment by Application
5.1 Global PEGylated Granulocyte-Colony Stimulating Factor Sales by Application (2019-2030)
5.1.1 Global PEGylated Granulocyte-Colony Stimulating Factor Sales by Application (2019-2024)
5.1.2 Global PEGylated Granulocyte-Colony Stimulating Factor Sales by Application (2025-2030)
5.1.3 Global PEGylated Granulocyte-Colony Stimulating Factor Sales Market Share by Application (2019-2030)
5.2 Global PEGylated Granulocyte-Colony Stimulating Factor Revenue by Application (2019-2030)
5.2.1 Global PEGylated Granulocyte-Colony Stimulating Factor Revenue by Application (2019-2024)
5.2.2 Global PEGylated Granulocyte-Colony Stimulating Factor Revenue by Application (2025-2030)
5.2.3 Global PEGylated Granulocyte-Colony Stimulating Factor Revenue Market Share by Application (2019-2030)
5.3 Global PEGylated Granulocyte-Colony Stimulating Factor Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Amgen
6.1.1 Amgen Company Information
6.1.2 Amgen Description and Business Overview
6.1.3 Amgen PEGylated Granulocyte-Colony Stimulating Factor Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Amgen PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio
6.1.5 Amgen Recent Developments/Updates
6.2 Mylan
6.2.1 Mylan Company Information
6.2.2 Mylan Description and Business Overview
6.2.3 Mylan PEGylated Granulocyte-Colony Stimulating Factor Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Mylan PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio
6.2.5 Mylan Recent Developments/Updates
6.3 Kashiv BioSciences
6.3.1 Kashiv BioSciences Company Information
6.3.2 Kashiv BioSciences Description and Business Overview
6.3.3 Kashiv BioSciences PEGylated Granulocyte-Colony Stimulating Factor Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Kashiv BioSciences PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio
6.3.5 Kashiv BioSciences Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Company Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer PEGylated Granulocyte-Colony Stimulating Factor Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Pfizer PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Fresenius Kabi
6.5.1 Fresenius Kabi Company Information
6.5.2 Fresenius Kabi Description and Business Overview
6.5.3 Fresenius Kabi PEGylated Granulocyte-Colony Stimulating Factor Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Fresenius Kabi PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio
6.5.5 Fresenius Kabi Recent Developments/Updates
6.6 Coherus BioSciences
6.6.1 Coherus BioSciences Company Information
6.6.2 Coherus BioSciences Description and Business Overview
6.6.3 Coherus BioSciences PEGylated Granulocyte-Colony Stimulating Factor Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Coherus BioSciences PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio
6.6.5 Coherus BioSciences Recent Developments/Updates
6.7 Sandoz
6.7.1 Sandoz Company Information
6.7.2 Sandoz Description and Business Overview
6.7.3 Sandoz PEGylated Granulocyte-Colony Stimulating Factor Sales, Revenue and Gross Margin (2019-2024)
6.7.4 Sandoz PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio
6.7.5 Sandoz Recent Developments/Updates
6.8 Jiangsu Hengrui Pharmaceuticals
6.8.1 Jiangsu Hengrui Pharmaceuticals Company Information
6.8.2 Jiangsu Hengrui Pharmaceuticals Description and Business Overview
6.8.3 Jiangsu Hengrui Pharmaceuticals PEGylated Granulocyte-Colony Stimulating Factor Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Jiangsu Hengrui Pharmaceuticals PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio
6.8.5 Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
6.9 Amoytop Biotech
6.9.1 Amoytop Biotech Company Information
6.9.2 Amoytop Biotech Description and Business Overview
6.9.3 Amoytop Biotech PEGylated Granulocyte-Colony Stimulating Factor Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Amoytop Biotech PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio
6.9.5 Amoytop Biotech Recent Developments/Updates
6.10 Qilu Pharmaceutical
6.10.1 Qilu Pharmaceutical Company Information
6.10.2 Qilu Pharmaceutical Description and Business Overview
6.10.3 Qilu Pharmaceutical PEGylated Granulocyte-Colony Stimulating Factor Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Qilu Pharmaceutical PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio
6.10.5 Qilu Pharmaceutical Recent Developments/Updates
6.11 CSPC Baike Biopharma
6.11.1 CSPC Baike Biopharma Company Information
6.11.2 CSPC Baike Biopharma Description and Business Overview
6.11.3 CSPC Baike Biopharma PEGylated Granulocyte-Colony Stimulating Factor Sales, Revenue and Gross Margin (2019-2024)
6.11.4 CSPC Baike Biopharma PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio
6.11.5 CSPC Baike Biopharma Recent Developments/Updates
6.12 SL Pharm
6.12.1 SL Pharm Company Information
6.12.2 SL Pharm Description and Business Overview
6.12.3 SL Pharm PEGylated Granulocyte-Colony Stimulating Factor Sales, Revenue and Gross Margin (2019-2024)
6.12.4 SL Pharm PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio
6.12.5 SL Pharm Recent Developments/Updates
6.13 Lunan Pharmaceutical
6.13.1 Lunan Pharmaceutical Company Information
6.13.2 Lunan Pharmaceutical Description and Business Overview
6.13.3 Lunan Pharmaceutical PEGylated Granulocyte-Colony Stimulating Factor Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Lunan Pharmaceutical PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio
6.13.5 Lunan Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 PEGylated Granulocyte-Colony Stimulating Factor Industry Chain Analysis
7.2 PEGylated Granulocyte-Colony Stimulating Factor Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 PEGylated Granulocyte-Colony Stimulating Factor Production Mode & Process
7.4 PEGylated Granulocyte-Colony Stimulating Factor Sales and Marketing
7.4.1 PEGylated Granulocyte-Colony Stimulating Factor Sales Channels
7.4.2 PEGylated Granulocyte-Colony Stimulating Factor Distributors
7.5 PEGylated Granulocyte-Colony Stimulating Factor Customers
8 PEGylated Granulocyte-Colony Stimulating Factor Market Dynamics
8.1 PEGylated Granulocyte-Colony Stimulating Factor Industry Trends
8.2 PEGylated Granulocyte-Colony Stimulating Factor Market Drivers
8.3 PEGylated Granulocyte-Colony Stimulating Factor Market Challenges
8.4 PEGylated Granulocyte-Colony Stimulating Factor Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global PEGylated Granulocyte-Colony Stimulating Factor Market Value Comparison by Type (2024-2030) & (US$ Million)
 Table 2. Global PEGylated Granulocyte-Colony Stimulating Factor Market Value by Application (2024-2030) & (US$ Million)
 Table 3. Global PEGylated Granulocyte-Colony Stimulating Factor Market Competitive Situation by Manufacturers in 2023
 Table 4. Global PEGylated Granulocyte-Colony Stimulating Factor Sales (K Units) of Key Manufacturers (2019-2024)
 Table 5. Global PEGylated Granulocyte-Colony Stimulating Factor Sales Market Share by Manufacturers (2019-2024)
 Table 6. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue (US$ Million) by Manufacturers (2019-2024)
 Table 7. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue Share by Manufacturers (2019-2024)
 Table 8. Global Market PEGylated Granulocyte-Colony Stimulating Factor Average Price (US$/Unit) of Key Manufacturers (2019-2024)
 Table 9. Global Key Players of PEGylated Granulocyte-Colony Stimulating Factor, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of PEGylated Granulocyte-Colony Stimulating Factor, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of PEGylated Granulocyte-Colony Stimulating Factor, Product Type & Application
 Table 12. Global Key Manufacturers of PEGylated Granulocyte-Colony Stimulating Factor, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global PEGylated Granulocyte-Colony Stimulating Factor by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PEGylated Granulocyte-Colony Stimulating Factor as of 2023)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global PEGylated Granulocyte-Colony Stimulating Factor Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Table 17. Global PEGylated Granulocyte-Colony Stimulating Factor Sales by Region (2019-2024) & (K Units)
 Table 18. Global PEGylated Granulocyte-Colony Stimulating Factor Sales Market Share by Region (2019-2024)
 Table 19. Global PEGylated Granulocyte-Colony Stimulating Factor Sales by Region (2025-2030) & (K Units)
 Table 20. Global PEGylated Granulocyte-Colony Stimulating Factor Sales Market Share by Region (2025-2030)
 Table 21. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue by Region (2019-2024) & (US$ Million)
 Table 22. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue Market Share by Region (2019-2024)
 Table 23. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue by Region (2025-2030) & (US$ Million)
 Table 24. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue Market Share by Region (2025-2030)
 Table 25. North America PEGylated Granulocyte-Colony Stimulating Factor Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 26. North America PEGylated Granulocyte-Colony Stimulating Factor Sales by Country (2019-2024) & (K Units)
 Table 27. North America PEGylated Granulocyte-Colony Stimulating Factor Sales by Country (2025-2030) & (K Units)
 Table 28. North America PEGylated Granulocyte-Colony Stimulating Factor Revenue by Country (2019-2024) & (US$ Million)
 Table 29. North America PEGylated Granulocyte-Colony Stimulating Factor Revenue by Country (2025-2030) & (US$ Million)
 Table 30. Europe PEGylated Granulocyte-Colony Stimulating Factor Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 31. Europe PEGylated Granulocyte-Colony Stimulating Factor Sales by Country (2019-2024) & (K Units)
 Table 32. Europe PEGylated Granulocyte-Colony Stimulating Factor Sales by Country (2025-2030) & (K Units)
 Table 33. Europe PEGylated Granulocyte-Colony Stimulating Factor Revenue by Country (2019-2024) & (US$ Million)
 Table 34. Europe PEGylated Granulocyte-Colony Stimulating Factor Revenue by Country (2025-2030) & (US$ Million)
 Table 35. Asia Pacific PEGylated Granulocyte-Colony Stimulating Factor Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
 Table 36. Asia Pacific PEGylated Granulocyte-Colony Stimulating Factor Sales by Region (2019-2024) & (K Units)
 Table 37. Asia Pacific PEGylated Granulocyte-Colony Stimulating Factor Sales by Region (2025-2030) & (K Units)
 Table 38. Asia Pacific PEGylated Granulocyte-Colony Stimulating Factor Revenue by Region (2019-2024) & (US$ Million)
 Table 39. Asia Pacific PEGylated Granulocyte-Colony Stimulating Factor Revenue by Region (2025-2030) & (US$ Million)
 Table 40. Latin America PEGylated Granulocyte-Colony Stimulating Factor Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 41. Latin America PEGylated Granulocyte-Colony Stimulating Factor Sales by Country (2019-2024) & (K Units)
 Table 42. Latin America PEGylated Granulocyte-Colony Stimulating Factor Sales by Country (2025-2030) & (K Units)
 Table 43. Latin America PEGylated Granulocyte-Colony Stimulating Factor Revenue by Country (2019-2024) & (US$ Million)
 Table 44. Latin America PEGylated Granulocyte-Colony Stimulating Factor Revenue Market Share by Country (2019-2024)
 Table 45. Middle East and Africa PEGylated Granulocyte-Colony Stimulating Factor Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 46. Middle East and Africa PEGylated Granulocyte-Colony Stimulating Factor Sales by Country (2019-2024) & (K Units)
 Table 47. Middle East and Africa PEGylated Granulocyte-Colony Stimulating Factor Sales by Country (2025-2030) & (K Units)
 Table 48. Middle East and Africa PEGylated Granulocyte-Colony Stimulating Factor Revenue by Country (2019-2024) & (US$ Million)
 Table 49. Middle East and Africa PEGylated Granulocyte-Colony Stimulating Factor Revenue by Country (2025-2030) & (US$ Million)
 Table 50. Global PEGylated Granulocyte-Colony Stimulating Factor Sales (K Units) by Type (2019-2024)
 Table 51. Global PEGylated Granulocyte-Colony Stimulating Factor Sales (K Units) by Type (2025-2030)
 Table 52. Global PEGylated Granulocyte-Colony Stimulating Factor Sales Market Share by Type (2019-2024)
 Table 53. Global PEGylated Granulocyte-Colony Stimulating Factor Sales Market Share by Type (2025-2030)
 Table 54. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue (US$ Million) by Type (2019-2024)
 Table 55. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue (US$ Million) by Type (2025-2030)
 Table 56. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue Market Share by Type (2019-2024)
 Table 57. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue Market Share by Type (2025-2030)
 Table 58. Global PEGylated Granulocyte-Colony Stimulating Factor Price (US$/Unit) by Type (2019-2024)
 Table 59. Global PEGylated Granulocyte-Colony Stimulating Factor Price (US$/Unit) by Type (2025-2030)
 Table 60. Global PEGylated Granulocyte-Colony Stimulating Factor Sales (K Units) by Application (2019-2024)
 Table 61. Global PEGylated Granulocyte-Colony Stimulating Factor Sales (K Units) by Application (2025-2030)
 Table 62. Global PEGylated Granulocyte-Colony Stimulating Factor Sales Market Share by Application (2019-2024)
 Table 63. Global PEGylated Granulocyte-Colony Stimulating Factor Sales Market Share by Application (2025-2030)
 Table 64. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue (US$ Million) by Application (2019-2024)
 Table 65. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue (US$ Million) by Application (2025-2030)
 Table 66. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue Market Share by Application (2019-2024)
 Table 67. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue Market Share by Application (2025-2030)
 Table 68. Global PEGylated Granulocyte-Colony Stimulating Factor Price (US$/Unit) by Application (2019-2024)
 Table 69. Global PEGylated Granulocyte-Colony Stimulating Factor Price (US$/Unit) by Application (2025-2030)
 Table 70. Amgen Company Information
 Table 71. Amgen Description and Business Overview
 Table 72. Amgen PEGylated Granulocyte-Colony Stimulating Factor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 73. Amgen PEGylated Granulocyte-Colony Stimulating Factor Product
 Table 74. Amgen Recent Developments/Updates
 Table 75. Mylan Company Information
 Table 76. Mylan Description and Business Overview
 Table 77. Mylan PEGylated Granulocyte-Colony Stimulating Factor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 78. Mylan PEGylated Granulocyte-Colony Stimulating Factor Product
 Table 79. Mylan Recent Developments/Updates
 Table 80. Kashiv BioSciences Company Information
 Table 81. Kashiv BioSciences Description and Business Overview
 Table 82. Kashiv BioSciences PEGylated Granulocyte-Colony Stimulating Factor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 83. Kashiv BioSciences PEGylated Granulocyte-Colony Stimulating Factor Product
 Table 84. Kashiv BioSciences Recent Developments/Updates
 Table 85. Pfizer Company Information
 Table 86. Pfizer Description and Business Overview
 Table 87. Pfizer PEGylated Granulocyte-Colony Stimulating Factor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 88. Pfizer PEGylated Granulocyte-Colony Stimulating Factor Product
 Table 89. Pfizer Recent Developments/Updates
 Table 90. Fresenius Kabi Company Information
 Table 91. Fresenius Kabi Description and Business Overview
 Table 92. Fresenius Kabi PEGylated Granulocyte-Colony Stimulating Factor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 93. Fresenius Kabi PEGylated Granulocyte-Colony Stimulating Factor Product
 Table 94. Fresenius Kabi Recent Developments/Updates
 Table 95. Coherus BioSciences Company Information
 Table 96. Coherus BioSciences Description and Business Overview
 Table 97. Coherus BioSciences PEGylated Granulocyte-Colony Stimulating Factor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 98. Coherus BioSciences PEGylated Granulocyte-Colony Stimulating Factor Product
 Table 99. Coherus BioSciences Recent Developments/Updates
 Table 100. Sandoz Company Information
 Table 101. Sandoz Description and Business Overview
 Table 102. Sandoz PEGylated Granulocyte-Colony Stimulating Factor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 103. Sandoz PEGylated Granulocyte-Colony Stimulating Factor Product
 Table 104. Sandoz Recent Developments/Updates
 Table 105. Jiangsu Hengrui Pharmaceuticals Company Information
 Table 106. Jiangsu Hengrui Pharmaceuticals Description and Business Overview
 Table 107. Jiangsu Hengrui Pharmaceuticals PEGylated Granulocyte-Colony Stimulating Factor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 108. Jiangsu Hengrui Pharmaceuticals PEGylated Granulocyte-Colony Stimulating Factor Product
 Table 109. Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
 Table 110. Amoytop Biotech Company Information
 Table 111. Amoytop Biotech Description and Business Overview
 Table 112. Amoytop Biotech PEGylated Granulocyte-Colony Stimulating Factor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 113. Amoytop Biotech PEGylated Granulocyte-Colony Stimulating Factor Product
 Table 114. Amoytop Biotech Recent Developments/Updates
 Table 115. Qilu Pharmaceutical Company Information
 Table 116. Qilu Pharmaceutical Description and Business Overview
 Table 117. Qilu Pharmaceutical PEGylated Granulocyte-Colony Stimulating Factor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 118. Qilu Pharmaceutical PEGylated Granulocyte-Colony Stimulating Factor Product
 Table 119. Qilu Pharmaceutical Recent Developments/Updates
 Table 120. CSPC Baike Biopharma Company Information
 Table 121. CSPC Baike Biopharma Description and Business Overview
 Table 122. CSPC Baike Biopharma PEGylated Granulocyte-Colony Stimulating Factor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 123. CSPC Baike Biopharma PEGylated Granulocyte-Colony Stimulating Factor Product
 Table 124. CSPC Baike Biopharma Recent Developments/Updates
 Table 125. SL Pharm Company Information
 Table 126. SL Pharm Description and Business Overview
 Table 127. SL Pharm PEGylated Granulocyte-Colony Stimulating Factor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 128. SL Pharm PEGylated Granulocyte-Colony Stimulating Factor Product
 Table 129. SL Pharm Recent Developments/Updates
 Table 130. Lunan Pharmaceutical Company Information
 Table 131. Lunan Pharmaceutical Description and Business Overview
 Table 132. Lunan Pharmaceutical PEGylated Granulocyte-Colony Stimulating Factor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 133. Lunan Pharmaceutical PEGylated Granulocyte-Colony Stimulating Factor Product
 Table 134. Lunan Pharmaceutical Recent Developments/Updates
 Table 135. Key Raw Materials Lists
 Table 136. Raw Materials Key Suppliers Lists
 Table 137. PEGylated Granulocyte-Colony Stimulating Factor Distributors List
 Table 138. PEGylated Granulocyte-Colony Stimulating Factor Customers List
 Table 139. PEGylated Granulocyte-Colony Stimulating Factor Market Trends
 Table 140. PEGylated Granulocyte-Colony Stimulating Factor Market Drivers
 Table 141. PEGylated Granulocyte-Colony Stimulating Factor Market Challenges
 Table 142. PEGylated Granulocyte-Colony Stimulating Factor Market Restraints
 Table 143. Research Programs/Design for This Report
 Table 144. Key Data Information from Secondary Sources
 Table 145. Key Data Information from Primary Sources
 Table 146. Authors List of This Report


List of Figures
 Figure 1. Product Picture of PEGylated Granulocyte-Colony Stimulating Factor
 Figure 2. Global PEGylated Granulocyte-Colony Stimulating Factor Market Value Comparison by Type (2024-2030) & (US$ Million)
 Figure 3. Global PEGylated Granulocyte-Colony Stimulating Factor Market Share by Type: 2023 & 2030
 Figure 4. Pegfilgrastim Product Picture
 Figure 5. Mecapegfilgrastim Product Picture
 Figure 6. Telpegfilgrastim Product Picture
 Figure 7. Other Product Picture
 Figure 8. Global PEGylated Granulocyte-Colony Stimulating Factor Market Value by Application (2024-2030) & (US$ Million)
 Figure 9. Global PEGylated Granulocyte-Colony Stimulating Factor Market Share by Application: 2023 & 2030
 Figure 10. Hospital and Clinic
 Figure 11. Pharmacy
 Figure 12. Other
 Figure 13. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue, (US$ Million), 2019 VS 2023 VS 2030
 Figure 14. Global PEGylated Granulocyte-Colony Stimulating Factor Market Size (2019-2030) & (US$ Million)
 Figure 15. Global PEGylated Granulocyte-Colony Stimulating Factor Sales (2019-2030) & (K Units)
 Figure 16. Global PEGylated Granulocyte-Colony Stimulating Factor Average Price (US$/Unit) & (2019-2030)
 Figure 17. PEGylated Granulocyte-Colony Stimulating Factor Report Years Considered
 Figure 18. PEGylated Granulocyte-Colony Stimulating Factor Sales Share by Manufacturers in 2023
 Figure 19. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue Share by Manufacturers in 2023
 Figure 20. Global 5 and 10 Largest PEGylated Granulocyte-Colony Stimulating Factor Players: Market Share by Revenue in PEGylated Granulocyte-Colony Stimulating Factor in 2023
 Figure 21. PEGylated Granulocyte-Colony Stimulating Factor Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
 Figure 22. Global PEGylated Granulocyte-Colony Stimulating Factor Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Figure 23. North America PEGylated Granulocyte-Colony Stimulating Factor Sales Market Share by Country (2019-2030)
 Figure 24. North America PEGylated Granulocyte-Colony Stimulating Factor Revenue Market Share by Country (2019-2030)
 Figure 25. United States PEGylated Granulocyte-Colony Stimulating Factor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 26. Canada PEGylated Granulocyte-Colony Stimulating Factor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 27. Europe PEGylated Granulocyte-Colony Stimulating Factor Sales Market Share by Country (2019-2030)
 Figure 28. Europe PEGylated Granulocyte-Colony Stimulating Factor Revenue Market Share by Country (2019-2030)
 Figure 29. Germany PEGylated Granulocyte-Colony Stimulating Factor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 30. France PEGylated Granulocyte-Colony Stimulating Factor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 31. U.K. PEGylated Granulocyte-Colony Stimulating Factor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 32. Italy PEGylated Granulocyte-Colony Stimulating Factor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 33. Russia PEGylated Granulocyte-Colony Stimulating Factor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 34. Asia Pacific PEGylated Granulocyte-Colony Stimulating Factor Sales Market Share by Region (2019-2030)
 Figure 35. Asia Pacific PEGylated Granulocyte-Colony Stimulating Factor Revenue Market Share by Region (2019-2030)
 Figure 36. China PEGylated Granulocyte-Colony Stimulating Factor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 37. Japan PEGylated Granulocyte-Colony Stimulating Factor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 38. South Korea PEGylated Granulocyte-Colony Stimulating Factor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 39. India PEGylated Granulocyte-Colony Stimulating Factor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 40. Australia PEGylated Granulocyte-Colony Stimulating Factor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 41. China Taiwan PEGylated Granulocyte-Colony Stimulating Factor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 42. Southeast Asia PEGylated Granulocyte-Colony Stimulating Factor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 43. Latin America PEGylated Granulocyte-Colony Stimulating Factor Sales Market Share by Country (2019-2030)
 Figure 44. Mexico PEGylated Granulocyte-Colony Stimulating Factor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 45. Brazil PEGylated Granulocyte-Colony Stimulating Factor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 46. Argentina PEGylated Granulocyte-Colony Stimulating Factor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 47. Colombia PEGylated Granulocyte-Colony Stimulating Factor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 48. Middle East and Africa PEGylated Granulocyte-Colony Stimulating Factor Sales Market Share by Country (2019-2030)
 Figure 49. Middle East and Africa PEGylated Granulocyte-Colony Stimulating Factor Revenue Market Share by Country (2019-2030)
 Figure 50. Turkey PEGylated Granulocyte-Colony Stimulating Factor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 51. Saudi Arabia PEGylated Granulocyte-Colony Stimulating Factor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 52. UAE PEGylated Granulocyte-Colony Stimulating Factor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 53. Global Sales Market Share of PEGylated Granulocyte-Colony Stimulating Factor by Type (2019-2030)
 Figure 54. Global Revenue Market Share of PEGylated Granulocyte-Colony Stimulating Factor by Type (2019-2030)
 Figure 55. Global PEGylated Granulocyte-Colony Stimulating Factor Price (US$/Unit) by Type (2019-2030)
 Figure 56. Global Sales Market Share of PEGylated Granulocyte-Colony Stimulating Factor by Application (2019-2030)
 Figure 57. Global Revenue Market Share of PEGylated Granulocyte-Colony Stimulating Factor by Application (2019-2030)
 Figure 58. Global PEGylated Granulocyte-Colony Stimulating Factor Price (US$/Unit) by Application (2019-2030)
 Figure 59. PEGylated Granulocyte-Colony Stimulating Factor Value Chain
 Figure 60. PEGylated Granulocyte-Colony Stimulating Factor Production Process
 Figure 61. Channels of Distribution (Direct Vs Distribution)
 Figure 62. Bottom-up and Top-down Approaches for This Report
 Figure 63. Data Triangulation
 Figure 64. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

SecuX Technology Inc

SIMILAR REPORTS

RELATED REPORTS

Global GLP-1 Targeted Peptide Weight Loss Drugs Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-19A18322
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Stimulant-Free Fat Burners Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-3E3525
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Test Boosters Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-35T3049
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Salsalate Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-33Y1801
Thu Sep 11 00:00:00 UTC 2025

Add to Cart